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CBA/N mice possess  an  X-linked  immunodeficiency (xid) 1 characterized  by the 
inability  to  make  an  antibody response  to  various  helper  T  cell-independent  (TI) 
antigens,  low  immunoglobulin  (Ig)M  antibody  responses  to  some  helper  T  cell- 
dependent  antigens,  as  well  as  low serum  IgM and  IgG3 levels  (1-5).  This  xid  has 
been attributed to the absence of a subpopulation of B cells expressing Lyb 3, 5, and 
7 alloantigens (6-8). Also, B cells of xid mice express a low ratio of IgM to IgD surface 
Ig (9) and are extremely susceptible to the induction of immunological tolerance (10). 
Thus,  they share many characteristics with  immature B cells  (11)  and can be used 
with advantage in studies on antigen-specific B cell activation and differentiation. 
Mosier et  al.  (11)  have proposed that TI antigens can be placed into one of two 
categories, consisting of TI-1 antigens, which induce a  convincing immune response 
in xid mice, and TI-2 antigens, which do not. The original studies of Amsbaugh et al. 
(1,  2)  showed  that  CBA/N  mice  cannot  make  a  serum  antibody response  to  the 
lipopolysaccharide (LPS) of Escherichia  coli 0127, despite the fact that it elevates serum 
IgM levels  (2); the latter is due to the fact that LPS is a polyclonal activator (12) that 
induces B cells  of CBA/N mice to proliferate and synthesize Ig nonspecifically (13). 
Zaldivar and  Scher  (14) reported that xid mice immunized with  the LPS of E.  coli 
0114:B4  do  not  elicit  an  LPS-specific antibody  response.  Although  these  findings 
imply that xid mice cannot mount an antibody response to LPS per se, the results of 
preliminary studies conducted in our laboratory revealed that CBA/N mice produce 
a  reasonably good antibody response after immunization with a highly purified LPS 
derived from E.  coli  0113  (LPS 0113).  This suggests that  the ability of xid  mice to 
respond to LPS may depend largely upon the structural composition (serotype) of the 
LPS used. 
The present  work was designed to characterize the antibody response of CBA/N 
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mice  to  LPS  0113  in  greater  detail.  Because  one  could  argue  that  the  antibody 
response produced may be directed against lipid-A-associated protein found in some 
preparations  of LPS  (15-17),  only  LPS  prepared  by  the  phenol-water extraction 
procedure (18) was used; such preparations are considered to be free of contaminating 
lipoprotein (16, 17). Also, to establish that the antibody response of xid mice is specific 
for  the  O-polysaccharide  moiety  of  LPS,  the  native  protoplasmic  polysaccharide 
(NPP)  of E.  coli 0113 was used to prime mice for a  secondary antibody response to 
LPS 0113, as well as to inhibit the detection of antibody-producing plaque-forming 
cells (PFC) found after immunization  with LPS 0113. NPP is a simple polysaccharide 
product of aberrant bacterial metabolism; it is free of lipid A but, in mice, behaves as 
an antigen with specificity for LPS 0113 (19, 20) 
Recently,  we  derived  a  series  of hybridomas  that  make  monoclonal antibodies 
specific  for  LPS  0113;  these  monoclonal antibodies share  a  cross-reactive idiotype 
(IdX) expressed on LPS 0113-specific antibodies of all strains of mice examined (21). 
The expression of this IdX, which  is  neither allotype- nor major histocompatibility 
complex-restricted, also was examined for CBA/N mice immunized with LPS 0113. 
Materials and Methods 
Animals.  BALB/cCum mice were purchased from Cumberland View Farms, Clinton, TN. 
C3H/HeJ  and CBA/CaJ  mice were purchased from The Jackson Laboratory, Bar Harbor, 
ME.  CBA/N  (xid  mice)  as  well  as  C3H/HeN-MTV  + mice were  obtained from  the  Small 
Animal Section, Veterinary Resources Branch, Division  of Research Services, National Institutes 
of Health, Bethesda, MD. Only female mice, 6-8 wk old, were used in this work. 
Antigens  and Immunization  Procedure.  LPS 0113  was  extracted from the cell  walls of E.  coil 
0113 (Braude) by the phenol-water method (18). Details concerning its preparation, as well as 
its immunological properties, have been described (22); there is ample evidence to indicate that 
LPS 0113  is a TI antigen (20, 23-25). NPP was extracted with cold trichloroacetic acid (26) 
from the protoplasmic fraction of E. coli 0113 (Braude). Mice were immunized intraperitoneally 
with stated amounts of either LPS 0113 or NPP in 0.2 ml saline. 
Immunological Methods.  Antibody-producing PFC-making antibody specific  for  LPS  0113 
were  detected  by a  slide version of the  technique of localized hemolysis-in-gel using sheep 
erythrocytes (SRBC) sensitized with LPS 0113 as indicator cells (27). The results obtained for 
individual mice (PFC per spleen), which are log-normally distributed (28), are expressed  as 
log10 PFC per spleen +  SEM for groups of similarly treated mice. In all cases, corrections were 
made by subtraction of the number of SRBC-specific background PFC  found so  that  only 
values for LPS 0113-specific  PFC are considered in this work. 
A plaque-inhibition  test was used to establish that the antibody produced by PFC detected 
after immunization with LPS 0113  is directed against the  O-polysaccharide determinants of 
LPS 0113.  Here, different amounts of LPS 0113  or NPP were  added to the agarose-reaction 
mixture as inhibitors before assay for PFC. The percentage of PFC inhibited was then calculated 
with reference to control samples that contained no inhibitor. 
Numbers of LPS 0113-specific  PFC-secreting antibody possessing  an IdX also were  deter- 
mined by a plaque-inhibition  assay in which 50/zl of dilute (1:100) anti-IdX serum was added 
to the reaction mixture before the assay for PFC. The antiserum was prepared by immunizing 
(C.B20  X BALB/c)F~  mice with affinity-purified monoclonal antibody specific  for LPS 0113 
(21). 
Proliferative Response of Spleen Cells  to  LPS 011.3.  Spleens from  nonimmunized mice were 
removed aseptically and placed in Hanks' balanced salt solution supplemented with 5% fetal 
calf serum. Cell suspensions were prepared and then adjusted to the desired cell density before 
culture in Falcon 3040 microtiter trays (Falcon Labware, Oxnard, CA). Various numbers of 
spleen cells were cultured with different amounts of LPS 0113 for 4 d; [3H]thymidine (sp act, 
2 Ci/mmol) was added during the last 4 h of culture. Details concerning culture conditions, as HIERNAUX ET  AL.  1 199 
well as the procedure used to measure uptake of [3H]thymidine, have been described (29).  The 
results obtained are expressed as cpm 4- SEM for quadruplicate cultures. 
Statistics.  Student's  t  test  was  used  to  assess  the  significance of the  differences  observed. 
Differences were considered to be significant when P  values <0.05 were obtained. 
Results 
Proliferative and Primary Antibody  Responses  to  LPS 0113.  The  data  in  Table  I  show 
that  LPS 0113 does not induce a  significant  (P >  0.05)  proliferative response in spleen 
cells from  LPS-resistant  C3H/HeJ  mice.  By contrast,  it  stimulates  substantial  (P < 
0.05)  proliferative responses, at doses of 1.25-2.5/Lg, in spleen cells from LPS-sensitive 
C3H/HeN-MTV  +, BALB/cCum,  and CBA/N  mice. Because spleen cells from C3H/ 
HeJ  mice  can  give a  proliferative  response  to  lipid-A-associated  protein  but  not  to 
purified  LPS  (15-17),  these  findings  affirm  that  the  preparation  of LPS  0113  used, 
prepared  by the  phenol-water  method  (18),  does  not  contain  significant  amounts,  if 
any,  of lipid-A-associated  protein.  The  lower  proliferative  responses  of spleen  cells 
from CBA/N  mice most likely are due to a  lower percentage  of B  cells present  (11). 
CBA/N  mice given a  single intraperitoneal  injection of 20 ~g LPS 0113  produce  a 
reasonably  good primary  PFC  response 4  d  after immunization  (Table II). Although 
the  magnitude  of the  PFC  response  produced  was  less  than  that  of histocompatible 
CBA/CaJ  mice (P <  0.05)  in this particular experiment, the percentage of IdX ÷ PFC 
detected was the same for both strains  of mice (P >  0.05);  thus,  the expression of this 
IdX  is not affected in xid mice. 
TABLE  I 
Proliferative Response of Spleen Cells from  Various Strains of Mice to Different Amounts of LPS 0113 
Mouse strain 
Num- 
ber of 
cells 
per 
well 
gg LPS 0113 added per well 
0  0.1  0.5  2.0 
C3H/H~ 
C3H/HeN-MTV  ÷ 
BALB/cCum 
CBA/N 
X  10 .5 
0.5  936 4- 158"  1,477 4- 410  1,295 4- 440  1,573 4- 479 
1.25  1,534 4- 367  2,371 4- 520  1,489 4- 205  2,393 4- 1,356 
2.5  4,649 4- 1,399  5,095  4- 1,257  4,694 4- 2,255  3,989 4- 3,395 
5.0  6,417 4- 1,391  8,705 4- 2,688  7,167 4- 2,830  5,931 4- 3,274 
0.5  2,638 4- 1,407  41,053  4- 6,781  91,13l 4- 8,633  105,460  4- 17,119 
1.25  8,147 4- 796  71,396  +  I2,596  I02,982 +  5, I21  I06,830 +__ 20,962 
2.5  13,198  4- 2,652  50,209  +  3,796  56,214  4- 12,388  71,347  4- 16,148 
5.0  9,423 4- 2,924  31,176  4- 5,770  37,624  4- 2,724  25,124  4- 3,324 
0.5  1,607 4- 1,018  7,023  4- 1,375  23,824  4- 4,720  39,752  4- 2,072 
1.25  3,223  4- 1,059  26,918  4- 2,250  56,602  4- 4,147  86,365  4- 10,332 
2.5  12,401  4- 3,781  29,118  4- 3,157  55,805  4- 2,487  92,863  4- 12,998 
5.0  17,829  4- 3,902  30,632  4- 5,346  38,243  4- 10,639  43,095  4- 6,321 
0.5  820 4- 761  412 -  347  1,024 --- 770  1,725 4- 853 
1.25  599 4- 108  2,148 4- 768  4,568 +  809  7,623 +  2,885 
2.5  3,467 4- 1,255  13,066  4- 2,389  16,967  +  3,102  21,125  4- 8,015 
5.0  3,286 4- 843  19,763  4- 4,834  24,116  4- 8,203  35,616  4- 10,974 
* [aH]thymidine  incorporation  (cpm  4-  SEM)  after 4  d  of cell culture  in  the  presence  of LPS  0113; 
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TABLE  II 
PFC Response of CBA/Nand CBA/CaJ Mice to 20 I.tg LPS 011.3 
Number of  Percent  IdX  +  Mouse strain  PFC per spleen*  mice  PFC:~ 
CBA/N  20  3.593 + 0.134  46 +  8 
(3,922) 
CBA/CaJ  8  :3.845 +__ 0.087  45 -- 6 
(7,ooo) 
* Log10 PFC per spleen --- SEM for n mice, 4 d after immunization with 20/*g 
LPS 0113 i.p.; geometric means are in parentheses. 
Mean  percent  IdX  + PFC  ___ SEM  for n mice immunized with  20 /Lg LPS 
0113. 
TABLE  Iti 
Inhibition of PFC by LPS O113 or NPP  for Mice Immunized 
with 20 #g LPS 011.3" 
Percent inhibition  Mouse strain  Amount inhibitor added  of PFC} 
CBA/CaJ  50 btg LPS 0113  100 
100/*g LPS 0113  100 
50/*g NPP  81 
100 b~g NPP  77 
CBA/N  50 ~g LPS 0113  91 
100 #g LPS 0113  94 
50/*g NPP  69 
100/,g NPP  83 
* Plaque-inhibition assays were conducted using pooled spleen cell suspensions 
from five mice, 4 d after immunization with 20/zg LPS 0113. 
The values shown  represent  the means of triplicate assays that varied by no 
more than  10%. Each assay sample contained 90-100 PFC before addition 
of inhibitor. 
Specificity of PFC Produced after hnmunization  with LPS 0113.  CBA/N  and  CBA/CaJ 
mice were given a  single intraperitoneal  injection of 20/.tg LPS 0113.4  d  later, pooled 
spleen  cell suspensions  were  prepared  and  assayed  for  PFC  with  or without  50-100 
p.g LPS 0113 or NPP  added to the reaction mixture as inhibitors. The results obtained 
are expressed  as the  mean  percentage  of PFC  inhibited  by the addition  of LPS 0113 
or NPP;  controls consisted of assay samples containing no inhibitor. 
The results of the plaque-inhibition  test were similar for both strains of mice (Table 
III). The addition  of 50-100/*g LPS 0113  inhibited  the detection of virtually all PFC 
present,  whereas the addition  of 50-100/_tg  NPP  gave 70-80%  inhibition.  The degree 
of inhibition  noted  with  NPP  appeared  to  be  lower  than  that  obtained  with  LPS 
0113.  However,  this could  be attributed  to  the fact  that  NPP  has  a  lower molecular 
size and  epitope density  (19,  20);  thus,  larger amounts  of NPP  might  be required  for 
complete inhibition.  Nevertheless, these findings confirm that  the antibody  produced 
after  immunization  with  LPS  01 13  is directed  mainly  against  the  O-polysaccharide 
determinant  of LPS  0113,  rather  than  the  lipid-A-associated  protein  or some  other 
component  not  present  in  NPP. 
Secondary  Antibody  Response  to  LPS  0113.  Because  it  has  been  reported  that  LPS HIERNAUX ET AL.  1201 
0113  can  induce  a  secondary  (enhanced)  antibody  response  in  mice  pretreated 
(primed)  with  NPP  or LPS 0113  (20),  we examined whether a  secondary antibody 
response to LPS 0113 also could be induced in CBA/N as well as in other strains of 
mice considered  in  the.present  work.  Mice  were  primed with  different  amounts of 
either  NPP  or LPS  0113.  7,  14,  or 21  d  later,  they were  immunized with  10 lug of 
either  NPP  or LPS  0113  and  the magnitude  of the  PFC  response was assessed  4  d 
later. The results obtained were compared with those of unprimed mice immunized 
with  10 lug LPS 0113. 
C3H/HeN-MTV + and CBA/CaJ mice produced not only a good primary antibody 
response to  10 lug LPS 0113, but also a response that was 3-6 times greater (P <  0.05) 
when immunized after priming with a  single injection of 1-20 lug LPS 0113  (Table 
IV).  By contrast, C3H/HeJ mice produced an extremely low primary response to  10 
lug LPS 0113; this response was not increased  (P >  0.05)  after priming with  10-20 lug 
LPS 0113 and subsequent  immunization. This is consistent with the results of other 
studies showing that LPS 0113 induces only a weak in vivo primary antibody response 
(27, 30) and no secondary response (31)  in LPS-resistant  C3H/HeJ mice. 
CBA/N mice produced a reasonably good primary antibody response to 10 lug LPS 
0113; the response was 3-10 times greater (P< 0.05) in mice immunized after priming 
with 2-20 lug LPS 0113 (Table IV). CBA/N mice did not make a detectable antibody 
response to 10 lug NPP; however, priming with NPP resulted in a 5- to 10-fold increase 
(P <  0.05)  in the magnitude of the PFC response upon immunization with  10-20 lug 
LPS  0113.  By  contrast,  CBA/N  mice  primed  with  1 lug  NPP  made  only  a  weak 
antibody response  after  immunization with  10 lug NPP.  Because  NPP  is  composed 
mainly, if not exclusively, of the O-polysaccharide determinants of LPS 0113 (19, 20), 
TABLE IV 
Capacity of Various Strains of Mice to Give a Secondary PFC Response to LPS 0113 after 
Priming with LPS 0113 or NPP 
Immunization schedule 
Mouse strain  Number of mice  PFC per spleen* 
Day 0  Day 7  Day  14  Day 21 
C3H/HeN-MTV + 
CBA/C~I 
C3H/H~I 
CBA/N 
10  --  --  --  10lag LPS  3.613  ±  0.097  (4,106) 
10  10lag LPS  --  --  10~tg LPS  4.127  ±  0.077  (13,400) 
10  20 lag LPS  --  --  10 lag LPS  4.422  +  0.056  (26,417) 
10  --  --  10lag LPS  3.810 +  0.124  (6,453) 
9  1 /Lg LPS  --  10 lag LPS  4.248  :t: 0.097  (I 7,719) 
10  20 lag LPS  10 lag LPS  4.573  ±  0.058  (37,410) 
10  20/~g LPS  ]0 lag LPS  10/Lg LPS  10 #g LPS  3.739 +  0.130  (5,489) 
8  --  10 ,ug LPS  2.767  ±  0.235  (586) 
10  10 lag LPS  --  --  10/N I,PS  2.914  ±  0.089  (820) 
10  20 lag LPS  --  --  10 #g I.PS  2.792  ±  0.164  (619) 
10  --  10 #g LPS  3.586 +  0.063  (3,852) 
5  2/tg LPS  10/tg LPS  3.902  ±  0.129  (7,983) 
10  10/tg LPS  --  --  10 lag LPS  4.524±0.041  (33,442) 
10  211 lag LPS  --  --  10 lag LPN  4.370 +  0.060  (23,437) 
I0  20 lag 1.PS  10 lag LPS  10 #g LPS  10 lag I,PS  3.028  +  0.170  (1,067) 
10  --  10 #g NPP  (No response) 
10  I /tg NPP  --  --  10/tg NPP  2.736  ±  0.149  (545) 
10  I0 ,ttg NPP  --  --  10 #g LPS  4.223  ±  0.059  (16,706) 
10  20 lag NPP  --  20/Lg LPS  4.464  +  0.056  (29,130) 
* l.ogj0 PFC per spleen ±  SEM for n mice, 4 d  after the last  ir~jection  ofLPS 0113 or NPP: geometric means are in parentheses.  LPS 0113 was 
giwm intraperitoneally,  whereas NPP was given inu'avenously. 1202  ANTIBODY RESPONSE TO I,IPOPOLYSACCHARIDE 
TABLE V 
Dose-Response Relationshzps  for CBA/N Mice Irnmumzed with Different 
Amounts of LPS O113 
Immunizing dose  PFC per spleen* 
/*g 
0.2  2.116 + 0.307 (131) 
2.0  3.454 + 0.070 (2,844) 
10  3.778 -  0.067 (5,892) 
20  3.739 + 0.067 (5,488) 
40  3.756 +- 0.059 (5,705) 
* Logl0 PFC +-- SEM for eight mice, 4 d after intraperitoneal immunization 
with LPS 0113; geometric means are in parentheses. No LPS 0113-specific 
PFC were detected in nonimmunized CBA/N mice. 
4.0  I  I  I  I  I  1  I 
3.0 
.~2.0  I 
0  1  2  3  4  5  6  7  8 
DAY AFTER  IMMUNIZATION 
FIG.  l.  Kinetics  of the PFC response of CBA/N mice immunized intraperitoneally with 20 p.g 
LPS 0113. 
these findings, in addition to those of Table III, strongly suggest that (a) the antibody 
response produced is directed against the polysaccharide moiety of LPS 0113 rather 
than lipid-A-associated protein, and that (b) priming with NPP can prepare CBA/N, 
as well as other strains of mice (20), to give a secondary or increased antibody response 
to LPS 0113. 
When CBA/N mice were  hyperimmunized (i.e.,  given three weekly injections of 
LPS 0113) before immunization  with 10 ~g LPS 0113, the response produced was less 
(P <  0.05)  than that for a  primary response (Table IV). Hyperimmunized CBA/CaJ 
mice gave a  response similar in magnitude to that  for a  primary response (Table II), 
whereas  BALB/cCum  mice  gave  an  increased  response  (data  not  shown).  Thus, 
repeated exposure ofxid mice to LPS 0113 may result in a reduction in their capacity 
to make an antibody response to this antigen. 
Dose-Response  and  Kinetic  Studies for  the  Antibody  Response of  CBA/N  Mice  to  LPS 
0113.  Groups of CBA/N mice were given a  single injection of 0.2-40 #g i.p. of LPS 
0113  and the magnitude of the  PFC response produced was assessed  4  d  later. The 
results obtained (Table V) showed that the magnitude of the PFC response increased 
with the dose of LPS 0113  used  for immunization; maximal numbers of PFC were 
detected in mice inmmnized with  10-40/zg of antigen. In studies using other strains 
of mice  (27),  20 #g  of LPS  01 13  also  was  found  to  be  optimal  for  immunization. HIERNAUX ET AL.  1203 
Larger doses of LPS 0113 were not  given to CBA/N mice because amounts >40/~g 
were found to be too toxic for most strains of mice considered thus far (27). 
The  kinetics  for the  development  of a  PFC  response  in  CBA/N  mice  given  an 
optimally  immunogenic  dose  (20  /tg)  of LPS  0113  also  was  investigated  (Fig.  1). 
Although maximal numbers of PFC were first detected 3-4 d after immunization, the 
kinetics for the appearance of PFC showed a cyclic pattern with a periodicity different 
from that noted with other strains of mice (27). 
Discussion 
Studies  on  the  xid  of CBA/N  mice  have  provided  much  information  on  the 
differential,  as well  as  functional,  aspects of antigen-induced  B  cell  activation  (re- 
viewed  in  references  5  and  32).  Because  xid  mice can  make convincing  antibody 
responses  to some TI antigens  but  not  others,  it  has been convenient  to view such 
antigens as being one of two types; TI-1 antigens that elicit an antibody response in 
xid mice, and TI-2 antigens that do not (5,  11,  13). It has been proposed that xid mice 
lack  a  subpopulation  of B  cells  required  for  normal  antibody  responses  to  TI-2 
antigens  (reviewed in references 5 and 32). 
The inability  of xid mice to make an  antibody response to preparations of LPS 
derived  from  E.  coli  0127  (2)  and  E.  coli  0114:B4  (14)  led  some  investigators  to 
conclude  that  LPS  per  se  are  TI-2  antigens,  incapable  of inducing  an  antibody 
response  in  xid  mice  (reviewed in  references 5  and  32).  However, our faith  in  this 
generalization began to waiver when the results of preliminary experiments revealed 
that  xid  mice can elicit  a  significant  antibody response after immunization  with  a 
preparation  of LPS  derived  from  E.  coli 0113  (LPS  0113).  Consequently,  we were 
compelled to examine this response in greater detail to determine whether it is specific 
for the  O-polysaccharide moiety of LPS 0113,  or other components present  in some 
preparations  of LPS  from  other  sources,  isolated  by  different  methods.  Of major 
concern  was  the  possibility  that  the  antibody  response  made was  directed  against 
lipid-A-associated protein. 
The preparation of LPS 0113  used in this work has been shown unequivocally to 
be a TI antigen  (20,  23-25);  because it was prepared by the phenol-water method, it 
is thus not likely to contain significant amounts, if any, of lipid-A-associated protein 
(16,  17). LPS  0113  produced  substantial  mitogenic  responses  in  spleen  cells  from 
CBA/N, BALB/cCum, and LPS-sensitive C3H/HeN-MTV + mice. However, it stim- 
ulated no significant mitogenic responses in spleen cells from LPS-resistant C3H/HeJ 
mice (Table I). Furthermore, it induced a convincing PFC response in CBA/N mice 
(Table  II) and  virtually all  PFC  detected  could  be  inhibited  by NPP  (Table  III), 
which is free of lipid A as well as lipid-A-associated protein, and contains only the O- 
polysaccharide moiety of LPS 0113  (19, 33, 34).  LPS-resistant C3H/HeJ mice failed 
to  give convincing primary and  secondary antibody responses  to  LPS 0113  (Table 
IV);  this  is consistent  with  the  results  of others  (27,  30,  31).  However, substantial 
secondary responses to LPS 0113 were produced in CBA/N mice after priming with 
either LPS 0113 or NPP (Table IV). All of the above findings leave no doubt that the 
antibody response of CBA/N mice immunized with  LPS 0113  is specific for the  O- 
polysaccharide moiety of LPS. 
CBA/N  mice  immunized  with  20  /lg  LPS  0113  make  antibody  responses  that 
appear  to be  20-40%  lower  than  those  of histocompatible  nondefective CBA/CaJ 1204  ANTIBODY RESPONSE TO  LIPOPOLYSACCHARIDE 
mice (Tables II and IV), although dose-response and kinetic studies (Table V; Fig.  1) 
revealed few major differences from the results obtained with other strains of nonde- 
fective  mice  immunized  with  the  same  preparation  of LPS  0113  (27).  Unlike  the 
results obtained with xid mice immunized with phosphocholine conjugated to keyhole 
limpet hemocyanin or LPS, in which there is a  failure to produce the predominant 
(T-15) idiotype (35, 36), there is no change in the expression of a major IdX in CBA/ 
N  mice  immunized  with  LPS 0113  (Table  II).  However,  hyperimmunization  does 
appear to result  in a  significant  (P <  0.05)  decrease in the capacity of CBA/N mice 
to make an antibody response to this antigen  (Table IV). Obviously, more extensive 
studies are required to establish whether CBA/N mice are more susceptible than other 
strains of mice to the induction of immunological tolerance to LPS 0113. 
Despite the fact that LPS is considered to be a  TI antigen for mice, the ability of 
CBA/N mice to make an  antibody response to some types of LPS, but  not others, 
suggests that  it would be unwise to make general statements concerning the immu- 
nogenicity of this class  of antigens for xid mice. It is well known that some types of 
LPS  are  either  nonimmunogenic or  poorly immunogenic for many strains  of mice 
that  do  not  possess  the  xid  genetic  defect  (2). Also,  xid  mice,  as  well  as  several 
nondefective  strains  of mice  given  LPS,  can  make  polyclonal  antibody  responses 
(elevated levels of serum Ig) without the synthesis of antibody specific for some types 
of LPS  (2). Because  polyctonal activation  and  mitogenicity for B  cells  are  usually 
attributed  to the  action of lipid  A  or lipid-A-associated protein  in  the case of mice 
given LPS (12,  13), it  is unlikely that immunogenicity per se is determined by these 
components of the LPS complex. It is more reasonable to assume that the capacity of 
LPS to induce an antigen-specific antibody response resides  in the ability of B cells 
(a)  to recognize the O-polysaccharide moiety of LPS, and/or (b) to become activated 
with the synthesis and secretion of antibody specific for LPS upon recognition of O- 
polysaccharide determinants. With regard to the latter, the results of recent studies on 
the preparation of B cell  hybridomas making antibody specific for type III pneumo- 
coccal  polysaccharide  (SSS-III)  are  most  relevant  (37).  He,'e,  spleen  cells  from 
nonresponding xid mice immunized with SSS-III were fused with plasmacytoma cells 
that do not make antibody specific for SSS-III; genetic complementation occurred as 
evidenced  by the  fact  that  hybridomas making SSS-III-specific antibody were  ob- 
tained  in  high  frequency. This  means  that  B  cells  from  xid  mice  possess  V  region 
genes  involved  in  the  coding  of receptors  needed  for  the  recognition  of SSS-III. 
However,  such  cells,  even  after  exposure  to  SSS-III,  lack  an  internal  activation 
mechanism which permits the synthesis and/or secretion of SSS-III-specific antibody. 
Although the  nature  of this  activation  mechanism  remains  to  be  defined,  it  must 
involve genes linked to the X-chromosome. Such genes are known to play an important 
role  in  the  synthesis  and/or  secretion  of IgM  (1,  2,  38),  the  predominant  class  of 
antibody made after immunization with SSS-III (39, 40).  The ability of xid mice to 
respond to some thymus-independent hapten-carrier conjugates (5, 32)  may reflect a 
means  by  which  an  appropriate  carrier  can  bypass  to  some  degree  this  internal 
activation mechanism, which may be the major limiting factor in  determining IgM 
antibody responses to antigens such as  SSS-III. Obviously, a  more complete analysis 
of the  mechanisms  involved  in  the  xid  genetic  defect  would  add  greatly  to  our 
knowledge of certain immunodeficiency diseases in man, many of which are X linked. HIERNAUX  ET AL.  1205 
Summary 
CBA/N  mice,  which  possess  an  X-linked  immunodeficiency (xid),  produce  a 
convincing  antibody response to lipopolysaccharide derived from Escherichia coli 0113 
(LPS  0113),  a  thymus-independent antigen. The  antibody response  produced  was 
shown to be specific for the O-polysaccharide moiety of LPS 0113, rather than lipid 
A  or  lipid-A-associated protein. The relevance of this  finding to  the  nature of the 
genetic defect of xid-mice is discussed. 
Received  for publication 15 November 1982. 
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